New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 31, 2014
07:04 EDTCRISCuris announces removal of FDA partial clinical hold on CUDC-427
Curis reported that the FDA has notified the company that its complete response submission to the November 2013 partial clinical hold on CUDC-427 has been reviewed and that the FDA has determined that it is safe to proceed under the IND. The FDA also indicated that detailed official correspondence regarding the determination will be released in the near future. Curis will provide additional details, if applicable, based upon further communications from the FDA as they become available.
News For CRIS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 28, 2014
07:21 EDTCRISCuris announces allowance of U.S. patent
Curis announced the receipt of a Notice of Allowance of a U.S. patent that covers a broad genus of compounds that target histone deacetylase, or HDAC, and phosphoinositide 3-kinase, or PI3K, activities in a single chemical structure including CUDC-907, Curis' oral, dual HDAC and PI3K small molecule inhibitor that is currently being studied in Phase 1 clinical trials. This patent, along with prior patents issued to Curis, further strengthens the Company's intellectual property portfolio of compounds including CUDC-907 that inhibit HDAC and PI3K enzymes in a single small molecule for the treatment of certain human diseases. Collectively, these patents generically cover composition-of-matter and methods of use of CUDC-907 as well as a broad range of proprietary chemical entities that target HDAC and PI3K enzymes, and in some instances mammalian target of rapamycin, within a single molecule for the treatment of certain human diseases.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use